1302 Stock Overview
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders.
No risks detected for 1302 from our risk checks.
LifeTech Scientific Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$2.89|
|52 Week High||HK$5.86|
|52 Week Low||HK$2.01|
|1 Month Change||31.96%|
|3 Month Change||6.64%|
|1 Year Change||-41.50%|
|3 Year Change||103.52%|
|5 Year Change||56.22%|
|Change since IPO||1,056.00%|
Recent News & Updates
A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)
In this article we are going to estimate the intrinsic value of LifeTech Scientific Corporation ( HKG:1302 ) by...
Returns At LifeTech Scientific (HKG:1302) Are On The Way Up
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
|1302||HK Medical Equipment||HK Market|
Return vs Industry: 1302 exceeded the Hong Kong Medical Equipment industry which returned -60.3% over the past year.
Return vs Market: 1302 underperformed the Hong Kong Market which returned -23.3% over the past year.
|1302 Average Weekly Movement||7.6%|
|Medical Equipment Industry Average Movement||8.4%|
|Market Average Movement||7.0%|
|10% most volatile stocks in HK Market||13.8%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 1302 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 1302's weekly volatility (8%) has been stable over the past year.
About the Company
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, Heart, and Konara-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; delivery systems, such as Fustar steerable and SteerEase introducers; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; LawMax dilators; and SeQure snare systems, as well as pacemakers.
LifeTech Scientific Fundamentals Summary
|1302 fundamental statistics|
Is 1302 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1302 income statement (TTM)|
|Cost of Revenue||CN¥177.80m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.063|
|Net Profit Margin||31.61%|
How did 1302 perform over the long term?See historical performance and comparison
Is 1302 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1302?
Other financial metrics that can be useful for relative valuation.
|What is 1302's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 1302's PE Ratio compare to its peers?
|1302 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: 1302 is good value based on its Price-To-Earnings Ratio (39x) compared to the peer average (46.3x).
Price to Earnings Ratio vs Industry
How does 1302's PE Ratio compare vs other companies in the Medical Equipment Industry?
Price-To-Earnings vs Industry: 1302 is expensive based on its Price-To-Earnings Ratio (39x) compared to the Hong Kong Medical Equipment industry average (17.2x)
Price to Earnings Ratio vs Fair Ratio
What is 1302's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||39x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1302's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 1302 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1302 (HK$2.89) is trading above our estimate of fair value (HK$2.55)
Significantly Below Fair Value: 1302 is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1302's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is LifeTech Scientific forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as LifeTech Scientific has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine LifeTech Scientific's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- LifeTech Scientific competitive advantages and company strategy can generally be found in its financial reports archived here.
How has LifeTech Scientific performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1302 has high quality earnings.
Growing Profit Margin: 1302's current net profit margins (31.6%) are lower than last year (33.6%).
Past Earnings Growth Analysis
Earnings Trend: 1302's earnings have grown by 14.5% per year over the past 5 years.
Accelerating Growth: 1302's earnings growth over the past year (35.4%) exceeds its 5-year average (14.5% per year).
Earnings vs Industry: 1302 earnings growth over the past year (35.4%) underperformed the Medical Equipment industry 35.4%.
Return on Equity
High ROE: 1302's Return on Equity (11.2%) is considered low.
Discover strong past performing companies
How is LifeTech Scientific's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 1302's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥481.9M).
Long Term Liabilities: 1302's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥171.7M).
Debt to Equity History and Analysis
Debt Level: 1302 is debt free.
Reducing Debt: 1302 has no debt compared to 5 years ago when its debt to equity ratio was 22.9%.
Debt Coverage: 1302 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 1302 has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is LifeTech Scientific current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1302's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1302's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1302's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1302's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: 1302 is not paying a notable dividend for the Hong Kong market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 1302 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Yuehui Xie (52 yo)
Mr. Yuehui Xie has been the Chief Executive Officer at LifeTech Scientific Corporation since March 2, 2015. Mr. Xie is responsible for overall strategic planning and management of LifeTech Scientific Corpo...
CEO Compensation Analysis
Compensation vs Market: Yuehui's total compensation ($USD2.10M) is above average for companies of similar size in the Hong Kong market ($USD590.64K).
Compensation vs Earnings: Yuehui's compensation has increased by more than 20% in the past year.
Experienced Board: 1302's board of directors are considered experienced (8.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
LifeTech Scientific Corporation's employee growth, exchange listings and data sources
- Name: LifeTech Scientific Corporation
- Ticker: 1302
- Exchange: SEHK
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: HK$13.381b
- Shares outstanding: 4.63b
- Website: https://www.lifetechmed.com
Number of Employees
- LifeTech Scientific Corporation
- LifeTech Scientific Building
- No.22, Keji 12th Road South
- Guangdong Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/25 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.